Shanghai RAAS Blood Products Co Ltd Class A (002252) - Total Liabilities
Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) has total liabilities worth CN¥5.46 Billion CNY (≈ $798.84 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai RAAS Blood Products Co Ltd Class A - Total Liabilities Trend (2005–2025)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. See 002252 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Shanghai RAAS Blood Products Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Shanghai RAAS Blood Products Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cavco Industries Inc
NASDAQ:CVCO
|
USA | $387.96 Million |
|
Koninklijke Vopak NV
AS:VPK
|
Netherlands | €3.58 Billion |
|
Wuhan Raycus Fiber Laser Technologies Co Ltd Class A
SHE:300747
|
China | CN¥-3.48 Billion |
|
Vita Coco Company Inc
NASDAQ:COCO
|
USA | $136.17 Million |
|
Indian Railway Catering And Tourism Corporation Limited
NSE:IRCTC
|
India | Rs33.71 Billion |
|
TaTaTu SpA
PA:ALTTU
|
France | €48.74 Million |
|
BILFINGER SE UNSP.ADR 1/5
F:GBFU
|
Germany | €2.15 Billion |
|
JHT Design Co. Ltd. Cl A
SHG:603061
|
China | CN¥648.97 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Shanghai RAAS Blood Products Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai RAAS Blood Products Co Ltd Clas market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai RAAS Blood Products Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
The table below shows the annual total liabilities of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥5.34 Billion ≈ $780.86 Million |
+215.66% |
| 2024-12-31 | CN¥1.69 Billion ≈ $247.37 Million |
-25.81% |
| 2023-12-31 | CN¥2.28 Billion ≈ $333.44 Million |
+38.55% |
| 2022-12-31 | CN¥1.64 Billion ≈ $240.66 Million |
+23.43% |
| 2021-12-31 | CN¥1.33 Billion ≈ $194.97 Million |
+266.31% |
| 2020-12-31 | CN¥363.74 Million ≈ $53.23 Million |
+0.49% |
| 2019-12-31 | CN¥361.95 Million ≈ $52.96 Million |
-27.11% |
| 2018-12-31 | CN¥496.56 Million ≈ $72.66 Million |
-74.86% |
| 2017-12-31 | CN¥1.98 Billion ≈ $289.04 Million |
+32.10% |
| 2016-12-31 | CN¥1.50 Billion ≈ $218.81 Million |
+77.24% |
| 2015-12-31 | CN¥843.64 Million ≈ $123.45 Million |
+11.72% |
| 2014-12-31 | CN¥755.16 Million ≈ $110.50 Million |
+59.53% |
| 2013-12-31 | CN¥473.37 Million ≈ $69.27 Million |
+150.74% |
| 2012-12-31 | CN¥188.79 Million ≈ $27.63 Million |
+129.51% |
| 2011-12-31 | CN¥82.26 Million ≈ $12.04 Million |
-17.01% |
| 2010-12-31 | CN¥99.12 Million ≈ $14.50 Million |
+60.16% |
| 2009-12-31 | CN¥61.88 Million ≈ $9.06 Million |
-19.03% |
| 2008-12-31 | CN¥76.42 Million ≈ $11.18 Million |
-44.02% |
| 2007-12-31 | CN¥136.53 Million ≈ $19.98 Million |
-18.92% |
| 2006-12-31 | CN¥168.39 Million ≈ $24.64 Million |
+65.20% |
| 2005-12-31 | CN¥101.93 Million ≈ $14.92 Million |
-- |
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinoge… Read more